MCM
ANIP icon

Marathon Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Marathon Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.96M Sell
71,990
-600
-0.8% -$48.1K 1.21% 27
2026
Q1 		$5.58M Buy
72,590
+2,925
+4% +$228K 1.25% 26
2025
Q4 		$5.5M Sell
69,665
-40
-0.1% -$3.46K 1.18% 27
2025
Q3 		$6.38M Sell
69,705
-2,320
-3% -$189K 1.46% 22
2025
Q2 		$4.7M Buy
72,025
+2,830
+4% +$184K 1.2% 24
2025
Q1 		$4.63M Sell
69,195
-700
-1% -$41.8K 1.23% 26
2024
Q4 		$3.86M Sell
69,895
-150
-0.2% -$8.61K 0.97% 30
2024
Q3 		$4.18M Sell
70,045
-250
-0.4% -$15.3K 1.01% 27
2024
Q2 		$4.48M Sell
70,295
-875
-1% -$56.8K 1.14% 19
2024
Q1 		$4.92M Buy
71,170
+1,350
+2% +$81.5K 1.17% 25
2023
Q4 		$3.85M Sell
69,820
-1,850
-3% -$102K 0.97% 29
2023
Q3 		$4.16M Buy
71,670
+3,025
+4% +$175K 1.05% 28
2023
Q2 		$3.7M Sell
68,645
-16,245
-19% -$720K 0.91% 30
2023
Q1 		$3.37M Buy
84,890
+12,000
+16% +$506K 0.83% 32
2022
Q4 		$2.93M Hold
72,890
– – 0.81% 28
2022
Q3 		$2.34M Sell
72,890
-1,570
-2% -$53.7K 0.67% 35
2022
Q2 		$2.21M Sell
74,460
-550
-0.7% -$15.9K 0.71% 32
2022
Q1 		$2.11M Buy
75,010
+240
+0.3% +$8.95K 0.61% 41
2021
Q4 		$3.44M Buy
74,770
+575
+0.8% +$24.7K 0.81% 31
2021
Q3 		$2.44M Buy
+74,195
New +$2.31M 0.55% 37

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marathon Capital Management's ANIP Position: Q2 2026 in Review

Marathon Capital Management reduced its ANI Pharmaceuticals (ANIP) stake by 0.83% in Q2 2026, selling an estimated $48.1K and leaving 71,990 shares worth $5.96M. The position accounts for 1.21% of the portfolio, ranked #27.

Marathon Capital Management first reported a position in ANIP in Q3 2021 and has held it in 20 quarters since. The position peaked at $6.38M in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Marathon Capital Management held 71,990 shares of ANI Pharmaceuticals worth $5.96M as of Q2 2026.
  • Marathon Capital Management sold 600 ANI Pharmaceuticals shares in Q2 2026, an estimated $48.1K.
  • ANI Pharmaceuticals made up 1.21% of Marathon Capital Management's portfolio in Q2 2026, its #27 holding.
  • Marathon Capital Management first reported a position in ANI Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • Marathon Capital Management's ANI Pharmaceuticals position peaked at $6.38M in Q3 2025.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Marathon Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.